{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:44:33Z","timestamp":1790729073055,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":3150,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s13311-014-0304-z","type":"journal-article","created":{"date-parts":[[2014,9,24]],"date-time":"2014-09-24T15:40:25Z","timestamp":1411573225000},"page":"185-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"title":["Neuroprotective Properties of Cannabigerol in Huntington's Disease: Studies in R6\/2 Mice and 3-Nitropropionate-lesioned Mice"],"prefix":"10.1016","volume":"12","author":[{"given":"Sara","family":"Valdeolivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Navarrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cantarero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda L.","family":"Bellido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onintza","family":"Sagredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-014-0304-z_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-1-4419-6448-9_5","article-title":"Huntington's disease","volume":"685","author":"Roze","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"10.1007\/s13311-014-0304-z_bib2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington's disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol Rev"},{"key":"10.1007\/s13311-014-0304-z_bib3","doi-asserted-by":"crossref","first-page":"R98","DOI":"10.1093\/hmg\/ddq148","article-title":"Huntington's disease: progress toward effective disease-modifying treatments and a cure","volume":"19","author":"Johnson","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0304-z_bib4","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2174\/138161208785740108","article-title":"The endocannabinoid system in Huntington's disease","volume":"14","author":"Pazos","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1007\/s13311-014-0304-z_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1517\/14728221003709792","article-title":"The endocannabinoid system as a target for the treatment of neuronal damage","volume":"14","author":"Fern\u00e1ndez-Ruiz","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"10.1007\/s13311-014-0304-z_bib6","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1097\/00001756-200410250-00015","article-title":"Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo","volume":"15","author":"Lastres-Becker","year":"2004","journal-title":"Neuroreport"},{"key":"10.1007\/s13311-014-0304-z_bib7","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1460-9568.2007.05717.x","article-title":"Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors","volume":"26","author":"Sagredo","year":"2007","journal-title":"Eur J Neurosci"},{"key":"10.1007\/s13311-014-0304-z_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/brain\/awq278","article-title":"Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease","volume":"134","author":"Bl\u00e1zquez","year":"2011","journal-title":"Brain"},{"key":"10.1007\/s13311-014-0304-z_bib9","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain"},{"key":"10.1007\/s13311-014-0304-z_bib10","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/glia.20838","article-title":"Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease","volume":"57","author":"Sagredo","year":"2009","journal-title":"Glia"},{"key":"10.1007\/s13311-014-0304-z_bib11","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.neuropharm.2006.06.013","article-title":"The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum","volume":"51","author":"Pintor","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-014-0304-z_bib12","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1586\/ern.11.47","article-title":"THC and CBD oromucosal spray (Sativex\u00ae) in the management of spasticity associated with multiple sclerosis","volume":"11","author":"Sastre-Garriga","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"10.1007\/s13311-014-0304-z_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11539000-000000000-00000","article-title":"Role of cannabinoids in multiple sclerosis","volume":"25","author":"Zajicek","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1007\/s13311-014-0304-z_bib14","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/jnr.22682","article-title":"Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease","volume":"89","author":"Sagredo","year":"2011","journal-title":"J Neurosci Res"},{"key":"10.1007\/s13311-014-0304-z_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2125.2012.04341.x","article-title":"Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?","volume":"75","author":"Fern\u00e1ndez-Ruiz","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1007\/s13311-014-0304-z_bib16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/sj.bjp.0707423","article-title":"Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors","volume":"152","author":"O'Sullivan","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1007\/s13311-014-0304-z_bib17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","article-title":"Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb","volume":"30","author":"Izzo","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1007\/s13311-014-0304-z_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pharmthera.2011.09.002","article-title":"Phytocannabinoids as novel therapeutic agents in CNS disorders","volume":"133","author":"Hill","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1007\/s13311-014-0304-z_bib19","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1007\/s11481-012-9399-3","article-title":"A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis","volume":"7","author":"Granja","year":"2012","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1007\/s13311-014-0304-z_bib20","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.bcp.2013.01.017","article-title":"Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease","volume":"85","author":"Borrelli","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1007\/s13311-014-0304-z_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1476-5381.2009.00515.x","article-title":"Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist","volume":"159","author":"Cascio","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1007\/s13311-014-0304-z_bib22","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.1471-4159.2005.03515.x","article-title":"3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease","volume":"95","author":"Brouillet","year":"2005","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-014-0304-z_bib23","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/hmg\/ddq026","article-title":"Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression","volume":"19","author":"Pouladi","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0304-z_bib24","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0306-4522(02)00205-1","article-title":"Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl\/6 mice: behavioural and histopathological characterisation","volume":"114","author":"Fernagut","year":"2002","journal-title":"Neuroscience"},{"key":"10.1007\/s13311-014-0304-z_bib25","series-title":"Methods of enzyme analysis","first-page":"885","article-title":"Catalase","author":"Luck","year":"1971"},{"key":"10.1007\/s13311-014-0304-z_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0003-9861(78)90479-4","article-title":"Generation of superoxide radical during autoxidation of hydroxylamine and and assay for superoxide dismutase","volume":"186","author":"Kono","year":"1978","journal-title":"Arch Biochem Biophys"},{"key":"10.1007\/s13311-014-0304-z_bib27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0003-9861(59)90090-6","article-title":"Tissue sulfhydryl groups","volume":"82","author":"Ellman","year":"1978","journal-title":"Arch Biochem Biophys"},{"key":"10.1007\/s13311-014-0304-z_bib28","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","article-title":"Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice","volume":"28","author":"Gray","year":"2008","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-014-0304-z_bib29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1203\/PDR.0b013e318186e5dd","article-title":"Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets","volume":"64","author":"Alvarez","year":"2008","journal-title":"Pediatr Res"},{"key":"10.1007\/s13311-014-0304-z_bib30","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/hmg\/9.19.2799","article-title":"Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells","volume":"9","author":"Trettel","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0304-z_bib31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.0953-816X.2003.03131.x","article-title":"The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin","volume":"19","author":"Rangone","year":"2004","journal-title":"Eur J Neurosci"},{"key":"10.1007\/s13311-014-0304-z_bib32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/glia.20042","article-title":"CD44 overexpression by oligodendrocytes: a novel mouse model of inflammation-independent demyelination and dysmyelination","volume":"47","author":"Tuohy","year":"2004","journal-title":"Glia"},{"key":"10.1007\/s13311-014-0304-z_bib33","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"key":"10.1007\/s13311-014-0304-z_bib34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nbd.2007.04.012","article-title":"Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes","volume":"27","author":"Battista","year":"2007","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-014-0304-z_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mcn.2008.04.007","article-title":"CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6\/2 mice","volume":"39","author":"Apostol","year":"2008","journal-title":"Mol Cell Neurosci"},{"key":"10.1007\/s13311-014-0304-z_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.nbd.2008.12.017","article-title":"Glutamate toxicity in the striatum of the R6\/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters","volume":"34","author":"Estrada-S\u00e1nchez","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-014-0304-z_bib37","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/hmg\/9.9.1259","article-title":"Decreased expression of striatal signaling genes in a mouse model of Huntington's disease","volume":"9","author":"Luthi-Carter","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0304-z_bib38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.brainres.2006.02.102","article-title":"DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6\/2) reveals neuroinflammation and insulin associations","volume":"1088","author":"Crocker","year":"2006","journal-title":"Brain Res"},{"key":"10.1007\/s13311-014-0304-z_bib39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0006-8993(01)03000-1","article-title":"Reduced activity and protein expression of NOS in R6\/2 HD transgenic mice: effects of L-NAME on symptom progression","volume":"919","author":"Deckel","year":"2001","journal-title":"Brain Res"},{"key":"10.1007\/s13311-014-0304-z_bib40","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1523\/JNEUROSCI.23-06-02193.2003","article-title":"Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease","volume":"23","author":"Yu","year":"2003","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-014-0304-z_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/hmg\/ddi014","article-title":"Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1","volume":"14","author":"Zucker","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0304-z_bib42","doi-asserted-by":"crossref","first-page":"e54222","DOI":"10.1371\/journal.pone.0054222","article-title":"MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms","volume":"8","author":"Jovicic","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1007\/s13311-014-0304-z_bib43","doi-asserted-by":"crossref","first-page":"e27746","DOI":"10.1371\/journal.pone.0027746","article-title":"SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6\/2 mouse model of Huntington's disease","volume":"6","author":"Mielcarek","year":"2011","journal-title":"PLOS ONE"},{"key":"10.1007\/s13311-014-0304-z_bib44","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1471-4159.2009.06344.x","article-title":"Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons","volume":"111","author":"Rudinskiy","year":"2009","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-014-0304-z_bib45","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in Huntington's disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1007\/s13311-014-0304-z_bib46","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1176\/jnp.2006.18.4.553","article-title":"Nabilone could treat chorea and irritability in Huntington's disease","volume":"18","author":"Curtis","year":"2006","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1007\/s13311-014-0304-z_bib47","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/mds.22809","article-title":"A pilot study using nabilone for symptomatic treatment in Huntington's disease","volume":"24","author":"Curtis","year":"2009","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-014-0304-z_bib48","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/1531-8257(199911)14:6<1038::AID-MDS1024>3.0.CO;2-7","article-title":"Nabilone increases choreatic movements in Huntington's disease","volume":"14","author":"M\u00fcller-Vahl","year":"1999","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-014-0304-z_bib49","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/cn200114w","article-title":"Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors","volume":"3","author":"Valdeolivas","year":"2012","journal-title":"ACS Chem Neurosci"},{"key":"10.1007\/s13311-014-0304-z_bib50","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","volume":"219","author":"Deiana","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1007\/s13311-014-0304-z_bib51","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bbr.2009.06.031","article-title":"Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic alpha(2)-receptor levels in a transgenic Huntington's disease rat model","volume":"205","author":"Bode","year":"2009","journal-title":"Behav Brain Res"},{"key":"10.1007\/s13311-014-0304-z_bib52","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1006\/exnr.1998.6942","article-title":"Neuroprotective effects of the alpha2-adrenoceptor antagonists, (+)-efaroxan and (+\/\u2212)-idazoxan, against quinolinic acid-induced lesions of the rat striatum","volume":"154","author":"Martel","year":"1998","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-014-0304-z_bib53","doi-asserted-by":"crossref","first-page":"25628","DOI":"10.1074\/jbc.M804291200","article-title":"Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-\u03b3 (PPAR-\u03b3) in the pathogenesis of Huntington disease","volume":"283","author":"Quintanilla","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-014-0304-z_bib54","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/hmg\/ddr541","article-title":"Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease","volume":"21","author":"Johri","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-014-0304-z_bib55","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/jnc.12190","article-title":"Neuroprotective effects of PPAR-\u03b3 agonist rosiglitazone in N171-82Q mouse model of Huntington's disease","volume":"125","author":"Jin","year":"2013","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-014-0304-z_bib56","doi-asserted-by":"crossref","first-page":"7805","DOI":"10.1523\/JNEUROSCI.2038-05.2005","article-title":"The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice","volume":"25","author":"Sch\u00fctz","year":"2005","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-014-0304-z_bib57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/JAD-2007-11108","article-title":"Rosiglitazone induces mitochondrial biogenesis in mouse brain","volume":"11","author":"Strum","year":"2007","journal-title":"J Alzheimers Dis"},{"key":"10.1007\/s13311-014-0304-z_bib58","doi-asserted-by":"crossref","first-page":"11758","DOI":"10.1523\/JNEUROSCI.2461-07.2007","article-title":"Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration","volume":"27","author":"Strand","year":"2007","journal-title":"J Neurosci"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-014-0304-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-014-0304-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923008644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923008644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-014-0304-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:47:27Z","timestamp":1761806847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923008644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S1878747923008644"],"URL":"https:\/\/doi.org\/10.1007\/s13311-014-0304-z","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroprotective Properties of Cannabigerol in Huntington's Disease: Studies in R6\/2 Mice and 3-Nitropropionate-lesioned Mice","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-014-0304-z","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}